B‐cell–activating factor is elevated in serum of patients with myasthenia gravis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Sa-Yoon | - |
dc.contributor.author | Kang, Chul-Hoo | - |
dc.contributor.author | Lee, Keun-Hwa | - |
dc.date.accessioned | 2022-07-14T23:51:40Z | - |
dc.date.available | 2022-07-14T23:51:40Z | - |
dc.date.created | 2021-05-14 | - |
dc.date.issued | 2016-12 | - |
dc.identifier.issn | 0148-639X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/153326 | - |
dc.description.abstract | Introduction: Myasthenia gravis (MG) is a B-cell-mediated autoimmune disease. B-cell-activating factor (BAFF) is a major factor in B-cell development and activation. In this study we investigated serum BAFF levels in MG patients. Methods: We compared the serum BAFF levels of 20 MG patients with gender-matched healthy controls. We assayed serum concentrations of BAFF and anti-acetylcholine receptor antibody (AChR) titers. Results: Serum BAFF levels of MG patients with AChR antibodies were significantly higher than those of healthy controls. A significant positive correlation was observed between serum BAFF levels and anti-AChR antibody titers. BAFF values did not correlate with disease severity. Conclusions: BAFF may play a major role in the pathogenesis of MG, and it may provide a potential target for therapy in patients with MG. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.title | B‐cell–activating factor is elevated in serum of patients with myasthenia gravis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Keun-Hwa | - |
dc.identifier.doi | 10.1002/mus.25162 | - |
dc.identifier.scopusid | 2-s2.0-84991486040 | - |
dc.identifier.wosid | 000389625300008 | - |
dc.identifier.bibliographicCitation | MUSCLE & NERVE, v.54, no.6, pp.1030 - 1033 | - |
dc.relation.isPartOf | MUSCLE & NERVE | - |
dc.citation.title | MUSCLE & NERVE | - |
dc.citation.volume | 54 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1030 | - |
dc.citation.endPage | 1033 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.subject.keywordPlus | LYMPHOCYTE STIMULATOR | - |
dc.subject.keywordPlus | TNF FAMILY | - |
dc.subject.keywordPlus | T-CELL | - |
dc.subject.keywordPlus | BAFF | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | APRIL | - |
dc.subject.keywordPlus | DISORDERS | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | BLYS | - |
dc.subject.keywordAuthor | antibody | - |
dc.subject.keywordAuthor | autoimmune | - |
dc.subject.keywordAuthor | B-cell–activating factor | - |
dc.subject.keywordAuthor | myasthenia gravis | - |
dc.subject.keywordAuthor | pathogenesis | - |
dc.subject.keywordAuthor | therapy | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1002/mus.25162 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.